BL-8040, Pembrolizumab and Chemotherapy Deliver Promising Disease Control in Patients with Metastatic Pancreatic Adenocarcinoma
CXCR4 antagonist, BL-8040 modifies the tumour microenvironment
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
The QuIP Study Attempts to Harmonise the Use of TMB Panels
TMB is actively being studied as a predictive biomarker for identifying patients who might benefit from immunotherapy but the issue of variability between assays has been raised
Sitravatinib Plus Tislelizumab Show Promise in Platinum-Resistant Advanced Ovarian Cancer
Novel combination of sitravatinib and tislelizumab shows manageable safety and promising activity in phase Ib study
First-Line Combination Treatment with Durvalumab Plus Platinum and Etoposide Has Manageable Safety in ES-SCLC
Results from analyses of safety, pharmacokinetics and immunogenecity in the CASPIAN trial
First-line Nivolumab Plus Chemotherapy Did Not Meet the Primary Endpoint of Overall Survival in Non-Squamous NSCLC
Results of the CheckMate 227 - part 2 final analysis
Early Introduction of Corticosteroids May Alter the Efficacy of Immune Checkpoint Inhibitors
Two studies describe impact of the initiation of steroids early during the course of immune checkpoint inhibition on patient outcome
First-line Nivolumab Plus Ipilimumab is Safe and Provides Encouraging Survival in Patients with Advanced NSCLC and Co-Morbidity or Poor Performance Status
Nivolumab plus ipilimumab is effective regardless of PD-L1 expression levels in advanced NSCLC
Pembrolizumab May Be Considered as a First-Line Treatment Option in Non-Squamous NSCLC Even in the Presence of KRAS Mutations
Efficacy of pembrolizumab alone or combined with chemotherapy is solid regardless of KRAS mutations in non-squamous non-small cell lung cancer
A Daratumumab-Based Combination Shows a Significant Improvement in Overall Survival in Newly Diagnosed Multiple Myeloma
The results from the ALCYONE study
FDA Approves Atezolizumab With Nab-paclitaxel and Carboplatin for Metastatic Non-squamous NSCLC Without EGFR/ALK Aberrations
Evidence for efficacy is based on the results from the IMpower130 study
Cervical Cancer Ranked in the Top Three Cancers Affecting Women Younger Than 45 Years
It is a major public health problem particularly in less-resourced countries
FDA Approves Crizanlizumab-tmca and Voxelotor for Sickle Cell Disease
Evidence for efficacy for crizanlizumab-tmca is based on the results from the SUSTAIN trial and for voxelotor on the results from the HOPE study